Possible neuroleptic malignant syndrome during paliperidone administration: A case report

Journal of Clinical Psychopharmacology

Volumn 30, Issue 1, 2010, Pages 89-91

  Mantas, Christos ^a   Kalabokis, George ^a   Goulia, Panagiota ^a   Tourlakopoulos, Athanasios ^a   Hyphantis, Thomas ^a   Mavreas, Venetsanos ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; BROMOCRIPTINE; CLOZAPINE; CREATINE KINASE; CREATININE; DIAZEPAM; ELECTROLYTE; PALIPERIDONE; QUETIAPINE; VALPROIC ACID;

ADULT; BLOOD CELL COUNT; CASE REPORT; CREATININE BLOOD LEVEL; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG DOSE INCREASE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPHAGIA; ELECTROLYTE BLOOD LEVEL; EMERGENCY WARD; ENZYME BLOOD LEVEL; HUMAN; LETTER; MALE; MORNING DOSAGE; MUSCLE RIGIDITY; NEUROLEPTIC MALIGNANT SYNDROME; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROGNOSIS; PSYCHOSIS; SCHIZOPHRENIA; SEIZURE; UREA NITROGEN BLOOD LEVEL; VITAL SIGN;

ANTIPSYCHOTIC AGENTS; HUMANS; ISOXAZOLES; MALE; NEUROLEPTIC MALIGNANT SYNDROME; PSYCHIATRIC STATUS RATING SCALES; PYRIMIDINES; SCHIZOPHRENIA; YOUNG ADULT;

EID: 74549213827     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3181c9c7ef     Document Type: Letter

References (18)

1. Strawn JR, Keck PE Jr, Caroff SN. Neuroleptic malignant syndrome. Am J Psychiatry. 2007;164:870-876.
2. Adnet P, Lestavel P, Krivosic-Horber R. Neuroleptic malignant syndrome. Br J Anaesth. 2000;85:129-135.
3. Stubner S, Rustenbeck E, Grohmann R, et al. Severe and uncommon involuntary movement disorders due to psychotropic drugs. Pharmacopsychiatry. 2004;37:S54-S64.
4. Pope HG Jr, Keck PE Jr, McElroy SL. Frequency and presentation of neuroleptic malignant syndrome in a large psychiatric hospital. Am J Psychiatry. 1986;143: 1227-1233.
5. Susman VL. Clinical management of neuroleptic malignant syndrome. Psychiatric Q. 2001;72:325-336.
6. Picard LS, Lindsay S, Strawn JR, et al. Atypical neuroleptic malignant syndrome: diagnostic controversies and considerations. Pharmacotherapy. 2008;28:530-535.
7. Meltzer HY, Bobo WV, Nuamah IF, et al. Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studies. J Clin Psychiatry. 2008;69:817-829.
8. Duggal HS. Possible neuroleptic malignant syndrome associated with paliperidone. J Neuropsychiatry Clin Neurosci. 2007;19:477-478.
9. Margetic B, Aukst-Margetic B. Neuroleptic malignant syndrome and clozapine withdrawal at the same time? Prog Neuropsychopharmacol Biol Psychiatry. 2005;29:145-147.
10. Lee JW, Robertson S. Clozapine withdrawal catatonia and neuroleptic malignant syndrome: a case report. Ann Clin Psychiatry. 1997;9:165-169
11. Facciolà G, Avenoso A, Scordo MG, et al. Small effects of valproic acid on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenic or affective disorders. Ther Drug Monit. 1999; 21:341-345.
12. Ananth J, Parameswaran S, Gunatilake S, et al. Neuroleptic malignant syndrome and atypical antipsychotic drugs. J Clin Psychiatry. 2004;65:464-470.
13. Choi-Kain LW, Pope HG. Atypical neuroleptic malignant syndrome and the spectrum of malignant cerebrotoxic syndromes. Harv Rev Psychiatry. 2007;15:181-186.
14. Caroff SN, Francis A, Fricchione GL, et al. Catatonia: From Psychopathology to Neurobiology. Washington, DC: American Psychiatric Press; 2004.
15. Taylor MA, Fink M. Catatonia in psychiatric classification: a home of its own. Am J Psychiatry. 2003;160:1233-1241.
16. Fink M, Taylor MA. Catatonia: A Clinician's Guide to Diagnosis and Treatment. Cambridge, UK: Cambridge University Press; 2003.
17. Sharma R, Trappler B, Ng YK, et al. Risperidone-induced neuroleptic malignant syndrome. Ann Pharmacother. 1996;30: 775-778.
18. Janssen LP. Paliperidone Drug Information. Titusville, NJ: Janssen, L.P.; 2006.